Company Active LTD

Company profile

Seon Diagnostics Limited

Son Diagnostics Ltd.

Son Diagnostics is an early-stage company creating a suite of medical software products to automatically detect disease in medical images

CRN
07679157
Founded
2011
Age
15

Overview

Legal name
SEON DIAGNOSTICS LIMITED
Region
South East England
Registered address
OXFORD HOUSE
15 - 17 MOUNT EPHRAIM ROAD
TUNBRIDGE WELLS
ENGLAND
TN1 1EN
Insolvency history
No

Latest accounts

Financial period: 1 Jul 2024 to 30 Jun 2025

FILLETEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
6

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Mar
2027

Accounts due

Accounts Due

Next accounts due date

06 Jul
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Jun
2025

Accounts filed

Accounts

Last accounts made up date

22 Jun
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

22 Jun
2011

Incorporated

Inception

Company registered at Companies House

Public funding

4 awards
First funded
2018
Funded years
2018, 2019, 2020, 2022
Age at first award
6 years

Projects

2022 Collaborative R&D Lead participant

Automated Digital Diabetic Retinopathy Eye Screening System (ADDRESS)

1 Sep 2022 to 29 Feb 2024

Awarded
£349,759
Total cost £499,656

The ADDRESS project will enable Sēon Diagnostics Limited (SDL) to build upon extensive research and development activity to date and create the next generation system to automatically detect retinal abnormalities that are diabetic retinopathy in people living with diabetes. Every one of the estimated 460 million people living with diabetes1 is at risk of ...

2020 Feasibility Studies Lead participant

RetinaUWF COVID-19 Continuity

1 Jun 2020 to 31 Mar 2021

Awarded
£248,578
Total cost £248,578

no public description

2019 Collaborative R&D Lead participant

RetinaUWF - AI Detection of Diabetic Retinopathy in Ultra-Wide-Field Retinal Images

1 Oct 2019 to 30 Sep 2021

Awarded
£376,909
Total cost £538,443

"Diabetic Retinopathy (DR) is a common complication of diabetes mellitus, which affects around half of 430m diabetics worldwide (WHO). It is a major cause of blindness (\>7% UK blindness) but can be easily ameliorated if detected and treated early. Hence the importance of annual screening when images of the retina are taken and reviewed by qualified grade...

2018 Collaborative R&D Lead participant

RetinaScan: AI-enabled automated image assessment system for diabetic retinopathy screening

1 Mar 2018 to 31 Aug 2020

Awarded
£450,699
Total cost £643,856

"Diabetes mellitus (DM) is a global healthcare problem. In 2014 there were 422m diabetics, forecast to rise to 642m by 2040 \[WHO\]. Diabetic Retinopathy (DR) is a common complication (\>50% of sufferers) caused by physiological changes in the retina. It is a major cause of blindness (\>7% UK blindness) but easily ameliorated through laser or drug treatme...

Product types

Collaborative R&D Feasibility Studies